616880-14-9

Basic information

• Product Name: 4-METHANESULFONYLAMINOPHENYLBORONIC ACID, PINACOL ESTER
• Synonyms: N-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-PHENYL)METHANESULFONAMIDE;4-METHANESULFONYLAMINOPHENYLBORONIC ACID, PINACOL ESTER;4-(Methylsulfonamido)phenylboronic acid pinacol ester;4-Methylsulfonylaminophenylboronic acid,pinacol ester;Methanesulfonamide, N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-;4-(MethanesulfonaMido)phenylboronic acid pinacol ester, 97%;N-(Methylsulfonyl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)benzenaMine;4-(Methanesulfonylamino)phenylboronic acid pinacol ester 97%
• CAS NO: 616880-14-9
• Molecular Formula: C₁₃H₂₀BNO₄S
• Molecular Weight: 297.18
• Product Categories: Aryl;Organoborons;Aryl Boronate Esters;Boronate Esters;Boronic Acids and Derivatives;Chemical Synthesis;Organometallic Reagents
• Mol File: 616880-14-9.mol
• Article Data: 15

Chemical Properties

• Melting Point: 197-201 °C(lit.)
• Boiling Point: 414.226°C at 760 mmHg
• Flash Point: 204.317°C
• Appearance: /
• Density: 1.197g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.529
• Storage Temp.: 2-8°C
• PKA: 8.45±0.10(Predicted)
• CAS DataBase Reference: 4-METHANESULFONYLAMINOPHENYLBORONIC ACID, PINACOL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHANESULFONYLAMINOPHENYLBORONIC ACID, PINACOL ESTER(616880-14-9)
• EPA Substance Registry System: 4-METHANESULFONYLAMINOPHENYLBORONIC ACID, PINACOL ESTER(616880-14-9)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Safety Statements: 36
• WGK Germany: 3
• Hazardous Substances Data: 616880-14-9(Hazardous Substances Data)

Usage

Uses

2-(4-Methylsulfonylaminophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane is a reagent for the synthesis of selective irreversible BMX kinase inhibitor BMX-IN-1 with antitumor activity.

InChI:InChI=1/C13H20BNO4S/c1-12(2)13(3,4)19-14(18-12)10-6-8-11(9-7-10)15-20(5,16)17/h6-9,15H,1-5H3

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 214360-73-3 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)aniline 
• 106-40-1 4-bromo-aniline 
• 102294-59-7 N-(4-iodophenyl)-methanesulfonamide 
• 73183-34-3 bis(pinacol)diborane 
• 540-37-4 p-aminoiodobenzene 
• 4284-50-8 N-(4-bromophenyl)methanesulfonamide 

Downstream Products

• 1620952-02-4 N-(4'-(4-(hydrazinecarbonyl)-1,6-naphthyridin-2-yl)-[1,1'-biphenyl]-4-yl)methane sulfonamide 
• 1258624-12-2 N-(4-(5-aminopyridin-3-yl)phenyl)methanesulfonamide 
• 1371630-11-3 methyl 1-cyclopropyl-9-methyl-8-(4-(methylsulfonamido)phenyl)-4-oxo-4H-quinolizine-3-carboxylate 
• 1287792-53-3 7-(4-methanesulfonylaminophenyl)-2-phenyl-2H[1,2,3]triazolo[4,5-f]quinoline-9-carboxylic acid methyl ester 
• 1287792-57-7 N-[7-(4-methanesulfonylaminophenyl)-2-phenyl-2H-[1,2,3]-triazolo[4,5-f]quinoline-9-carbonyl]methanesulfonamide 
• 1287792-55-5 7-(4-methanesulfonylmethylaminophenyl)-2-phenyl-2H[1,2,3]-triazolo[4,5-f]quinoline-9-carboxylic acid methyl ester 
• 1287792-54-4 7-(4-methanesulfonylaminophenyl)-2-phenyl-2H[1,2,3]triazolo[4,5-f]quinoline-9-carboxylic acid 

Relevant articles and documents

Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration

Currently, the therapeutic options for treatment of liver failure are very limited. As mitogen-activated protein kinase kinase 4 (MKK4) has recently been identified by in vivo RNAi experiments to be a major regulator in hepatocyte regeneration, we pursued the development of a small molecule targeting this protein kinase. Starting from the approved BRAFV600E inhibitor vemurafenib (8), that showed a high off-target affinity to MKK4 in an initial screening, we followed a scaffold-hopping approach, changing the core heterocycle from 1H-pyrrolo[2,3-b]pyridine to 1H-pyrazolo[2,3-b]pyridine (10). Affinity to MKK4 could be conserved while the selectivity against off-target protein kinases was slightly improved. Further modifications led to 58 and 59 showing high affinity to MKK4 in the low nanomolar range and excellent selectivity profile from mandatory multiparameter-optimization for the essential anti-targets (MKK7, JNK1) and off-targets (BRAF, MAP4K5, ZAK) in the MKK4 pathway. Herein we report the first selective MKK4 inhibitors in this class.

Derivatives with uracil-benzothiazole structure, preparation method of derivatives, and application of anti-HCV drugs

According to the invention, a new series of uracil-benzothiazole NS5B RdRp inhibitors are designed and synthesized; the compounds have the structure shown in a general formula (1), wherein the uracil-benzothiazole NS5B RdRp inhibitor provided by the inven

Palladium-Catalyzed, Ring-Forming Aromatic C-H Alkylations with Unactivated Alkyl Halides

A catalytic C-H alkylation using unactivated alkyl halides and a variety of arenes and heteroarenes is described. This ring-forming process is successful with a variety of unactivated primary and secondary alkyl halides, including those with β-hydrogens. In contrast to standard polar or radical cyclizations of aromatic systems, electronic activation of the substrate is not required. The mild, catalytic reaction conditions are highly functional group tolerant and facilitate access to a diverse range of synthetically and medicinally important carbocyclic and heterocyclic systems.